Product image of Metformina + Vildagliptina Tolife (Metformin Hydrochloride, Vildagliptin) supplied by GNH India

Metformina + Vildagliptina Tolife

Active Ingredient:
Metformin Hydrochloride, Vildagliptin
Origin:
EU

Metformina + Vildagliptina Tolife (Metformin Hydrochloride, Vildagliptin)

Metformin Hydrochloride, the active ingredient in Metformina + Vildagliptina Tolife, is a biguanide presented as an oral tablet for oral use. Together with Vildagliptin, a DPP‑4 inhibitor, the combination is indicated for the management of type 2 diabetes mellitus in adult patients, helping to lower blood glucose by reducing hepatic glucose output and enhancing insulin secretion.

GNH India supplies Metformina + Vildagliptina Tolife as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and regulatory requirements across all markets.

Manufacturer / TM Owner

Towa Pharmaceutical S.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Metformina + Vildagliptina Tolife combines a biguanide and a DPP‑4 inhibitor to improve glycemic control in type 2 diabetes.

  • Type 2 diabetes mellitus (initial therapy): used as first‑line oral treatment to lower fasting and post‑prandial glucose.
  • Type 2 diabetes mellitus (add‑on therapy): added when metformin alone does not achieve glycemic targets.
  • Type 2 diabetes mellitus (combination therapy): employed together with other oral agents or insulin to achieve tighter control.

How It Works

  • Metformin activates AMP‑activated protein kinase, decreasing hepatic gluconeogenesis and increasing peripheral insulin sensitivity. Vildagliptin binds to and inhibits dipeptidyl peptidase‑4, prolonging the activity of incretin hormones GLP‑1 and GIP, which enhances glucose‑dependent insulin secretion and suppresses glucagon release, together producing improved glycemic control.

Side Effects

The most frequently reported reactions relate to the gastrointestinal tract and mild metabolic changes.

Common Side Effects

  • Nausea
  • Diarrhea
  • Abdominal discomfort
  • Headache
  • Dizziness
  • Mild hypoglycemia (especially with sulfonylureas or insulin)

Serious or Rare Side Effects

  • Lactic acidosis
  • Acute pancreatitis
  • Severe allergic reactions (e.g., Stevens‑Johnson syndrome)
  • Hepatic dysfunction
  • Renal impairment
  • Severe hypoglycemia

Precautions & Warnings

Careful assessment and monitoring are required to minimise risks associated with the combination therapy.

  • Renal function: assess eGFR before initiating and monitor periodically.
  • Hepatic impairment: use with caution; monitor liver enzymes.
  • Lactic acidosis risk: avoid in patients with significant renal or hepatic disease.
  • Hypoglycemia risk: monitor closely when combined with insulin or sulfonylureas.
  • Pregnancy and lactation: evaluate risk‑benefit; generally not recommended.
  • Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Avoid Interactions

Metformina + Vildagliptina Tolife may interact with several drug classes, requiring avoidance or close monitoring.

Major Interactions (Avoid)

  • Insulin or sulfonylureas: increased risk of severe hypoglycemia.
  • Iodinated contrast agents: may precipitate renal dysfunction and lactic acidosis.
  • Cimetidine: can raise metformin plasma concentrations.
  • Alcohol abuse: heightened risk of lactic acidosis.
  • Strong CYP2C9 inhibitors (e.g., fluconazole): may affect vildagliptin metabolism.

Moderate Interactions (Monitor Closely)

  • ACE inhibitors or ARBs: monitor renal function.
  • Diuretics: may alter renal clearance of metformin.
  • Beta‑blockers: can mask hypoglycemia symptoms.
  • Thyroid hormones: may influence glucose metabolism.
  • Rifampicin: may reduce vildagliptin plasma levels.

Frequently Asked Questions

Metformina + Vildagliptina Tolife is prescribed for adult patients with type 2 diabetes mellitus. The fixed‑dose combination of metformin and vildagliptin helps lower blood glucose by reducing hepatic glucose production and enhancing insulin secretion, providing an option for initial therapy or as an add‑on when glycemic targets are not met with a single agent.

Metformin Hydrochloride activates AMP‑activated protein kinase, which suppresses hepatic gluconeogenesis and improves peripheral insulin sensitivity. This results in reduced fasting glucose levels and better overall glycaemic control when used as part of the Metformina + Vildagliptina Tolife combination.

The specific dose and dosing schedule are determined by the prescribing clinician based on the patient’s clinical condition, renal function, and response to therapy. Healthcare professionals should follow local prescribing guidelines and adjust the regimen as needed.

Safety data in pregnancy and lactation are limited. The product should only be used if the potential benefit justifies the potential risk to the fetus or infant. Clinicians usually consider alternative therapies and closely monitor pregnant or nursing patients.

To place an enquiry, visit the product page on gnhindia.com and submit the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Metformina + Vildagliptina Tolife adds vildagliptin, a DPP‑4 inhibitor, to metformin. While metformin primarily reduces hepatic glucose output, vildagliptin enhances glucose‑dependent insulin secretion and suppresses glucagon. The combination can achieve better post‑prandial glucose control and may reduce the need for dose escalation of metformin alone.

Store the tablets at ambient temperature, preferably below 25 °C. Keep them in the original container, protect from moisture and direct sunlight, and ensure the packaging is tightly closed to maintain product stability.

The medication is taken orally, usually with meals to minimise gastrointestinal discomfort. Patients should swallow the tablets whole with a full glass of water and follow the dosing instructions provided by their healthcare professional.

The most serious adverse events include lactic acidosis, which can be life‑threatening, and acute pancreatitis. Severe hypoglycaemia may also occur, especially when the drug is combined with insulin or sulfonylureas. Prompt medical attention is required if any of these conditions develop.

Patients with severe renal impairment (eGFR <30 mL/min/1.73 m²), known hypersensitivity to metformin or vildagliptin, active liver disease, or a history of lactic acidosis should avoid this medication. It is also contraindicated in individuals with certain metabolic disorders such as acute or chronic metabolic acidosis.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Metformin Hydrochloride, Vildagliptin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT